Company News »

Cohen Milstein Sellers & Toll PLLC Announces the Investigation of EDAP TMS S.A.

Business Wire
Share on StockTwits
Published on

Cohen Milstein Sellers & Toll PLLC is conducting an investigation to determine whether EDAP TMS S.A. (“EDAP” or the “Company”) and certain of its officers and directors made false and misleading statements and/or omissions in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

A class action lawsuit was filed in the U.S. District Court for the Southern District of New York by another law firm on behalf of purchasers of the common stock of EDAP TMS S.A. (NASDAQ:EDAP) between February 1, 2013 and July 30, 2014, inclusive (the “Class Period”).

EDAP develops, produces, and markets minimally invasive medical devices for the treatment of urological diseases, including for the destruction of localized tumors. It offers Ablatherm, a High Intensity Focused Ultrasound (HIFU) based device for the treatment of organ-confined prostate cancer. The complaint alleges that EDAP and certain of its officers and directors (“Defendants”) misrepresented and/or failed to disclose that: (1) the Company overstated the efficacy of the Ablatherm-HIFU device by relying on cross-study comparisons rather than a head-to-head trial; (2) the metastasis-free survival rate was an inappropriate endpoint for this patient population; and (3) as a result of the foregoing, the Company’s statements about its business, operations, and prospects, including statements about the Ablatherm-HIFU device’s prospects for FDA approval, were materially false and misleading and/or lacked a reasonable basis.

The claims in this case followed the drop in EDAP shares after a unanimous vote by the FDA Gastroenterology and Urology Devices Panel against approval of the Company’s Ablatherm device for the treatment of prostate cancer based on the finding that EDAP had failed to demonstrate the efficacy of the device or that the benefits of the device outweighed its risks. The price of EDAP shares fell from $3.42 to $1.92 on July 31.

Cohen Milstein encourages all investors who purchased EDAP common stock between February 1, 2013 and July 30, 2014, or former employees with information concerning this matter to contact the firm.

If you are an EDAP shareholder and would like to discuss your right to recover for your economic loss, you may, without any cost or obligation, call Cohen Milstein’s Managing Partner, Steven J. Toll at (888) 240-0775 or (202) 408-4600, or email him at stoll@cohenmilstein.com. If you wish to serve as lead plaintiff, you must move the Court no later than October 3, 2014 to request appointment. Any member of the proposed class may retain Cohen Milstein or other attorneys to serve as your counsel in this action, or you may do nothing and remain an absent class member.

Cohen Milstein has significant experience in prosecuting investor class actions and actions involving securities fraud, and is active in major litigation pending in federal and state courts throughout the nation. Cohen Milstein has taken a lead role in numerous important cases on behalf of defrauded investors, and has been responsible for a number of outstanding recoveries which, in the aggregate, total over two billion dollars. Prior results do not guarantee a similar outcome. For more information visit www.cohenmilstein.com.

If you have any questions about this notice or the action, or with regard to your rights, please contact either of the following:

Steven J. Toll, Esq.
Rhys Tucker
Cohen Milstein Sellers & Toll PLLC
1100 New York Avenue, N.W.
Suite 500, East Tower
Washington, D.C. 20005
Telephone: (888) 240-0775 or (202) 408-4600
Email: stoll@cohenmilstein.com; rtucker@cohenmilstein.com

Attorney Advertising

Share on StockTwits